BridgeBio Pharma’s Attruby (acoramidis) receives FDA approval for treating ATTR-CM, marking a significant advancement in addressing this rare cardiovascular disease. The drug’s unique mechanism and positive Phase 3 trial results offer hope for patients, while its market positioning relative to Pfizer’s tafamidis sparks industry discussion.